JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Bacillus velezensis inhibits azoxymethane/dextran sulphate sodium induced colitis associated colorectal cancer via the small molecule HeLM

  • 0Department of Biomedical Science, The Bourne Laboratory, Royal Holloway University of London, London, UK.
Journal of Gastrointestinal Oncology +

|

May 19, 2025

|

May 19, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Bacillus velezensis EHv5 significantly reduces chronic colitis and colitis-associated colorectal cancer (CAC) in mice. The secondary metabolite HeLM is key to EHv5’s therapeutic effect, offering sustained inflammation amelioration and reduced tumor development.

Area Of Science

  • Gastroenterology
  • Microbiology
  • Oncology

Background

  • Ulcerative colitis (UC) is a chronic inflammatory colon condition with increased risk of colitis-associated colorectal cancer (CAC).
  • Bacillus velezensis EHv5 ameliorates acute colitis via the secondary metabolite HeLM.
  • The long-term efficacy of EHv5 in chronic UC and CAC prevention remains uninvestigated.

Purpose Of The Study

  • To evaluate the therapeutic potential of EHv5 in chronic UC.
  • To assess EHv5's ability to prevent CAC in a chronic colitis model.

Main Methods

  • Murine model using azoxymethane (AOM) and dextran sulphate sodium (DSS) to induce CAC and chronic colitis.
  • Treatment groups included negative control, positive control, EHv5, and an EHv5 mutant lacking HeLM production.
  • Assessment via clinical, biochemical, endoscopic measures, a novel Chronic Colitis Associated Cancer Activity Index (CACI), and histological analysis.

Main Results

  • EHv5 significantly reduced colitis severity and chronicity compared to controls, evidenced by clinical, endoscopic, and faecal calprotectin measures.
  • Tumor incidence was significantly lower in the EHv5 group (20%) versus the positive control (80%).
  • The CACI score proved more sensitive than DAI in reflecting disease progression.

Conclusions

  • EHv5 demonstrates sustained amelioration of chronic colitis in a murine model.
  • EHv5 significantly reduces the risk of CAC development, with HeLM identified as the crucial mediator.
  • These findings support EHv5 as a potential therapeutic agent for chronic UC and CAC prevention.

Keywords:

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD 01:29

544

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs that Destabilize Microtubules 01:10

4.0K

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Drugs that Stabilize Microtubules 01:15

2.8K

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...